What are CML CABs?
Our Community Advisory Board (CAB) is a diverse, global panel of 25 leading patient advocates from all world regions. Established in 2016 based on the HIV model, we have set up this CAB of patient representatives to act as a link between the patient community and researchers to provide valuable insights, guidance, and feedback to ensure our programs and initiatives align with real community needs.
CML-CAB members work together to address issues of strategic importance to the community at large and advocate for the best possible research and equal access to the most innovative treatment & care for CML patients around the world.
CML-CAB monitors pharmaceutical developments and research in CML through active and targeted interaction, long-term cooperation and continued dialogue with pharmaceutical partners, regulators, medical experts, and the scientific CML-community.
How do they work?
CABs require extensive preparation and planning between all members to make sure that all topics of importance to the community are thoroughly addressed and discussed. Typically, the whole process spans anywhere between 5-8 months and can involve around 30 participants including representatives from both sides. It is important to note that CML-CABs are an initiative of the patient community and therefore:
- CML-CAB invites participants from companies or academia.
- CML-CAB sets to work on the agenda for a two-way dialogue and pick the topics that are most meaningful to us.
- CML-CAB must respect confidentiality to have a trusted and open dialogue
- CML-CAB reports to its members through our regional CAB members & written report
- CML-CAB ensures follow-up through the CAB office and does not leave it as a one-off meeting
- CML-CAB trains CAB members on findings to help grow leaders into great advocates.
Interested in getting involved? Contact anastasia@cmladvocates.net for further information.
Find out more about our CML-CABs watching our video here!
